Home › NCT04829136

Sustained Oral Fiber Supplementation for Patients Undergoing Treatment for Hematological Malignancies

Feasibility of Implementing Sustained Oral Fiber Supplementation for Patients Undergoing Treatment for Hematological Malignancies

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Able to provide written informed consent prior to initiation of any study procedures
* Any diagnosed hematological malignancy
* At least 18 years of age
* Planned treatment at Fred Hutchinson Cancer Center and/or University of Washington Medical Center

Exclusion Criteria:

* Major psychiatric diagnosis that impairs cognitive functioning or is not controlled at the time of the approach, as judged by the patient's medical team
* Pregnant or breastfeeding. Pregnancy test is obtained as part of pre-transplant evaluation in women of child-bearing potential at arrival to transplant and again within 7 days of conditioning and will be confirmed as negative by review of the chart

About the study

This clinical trial examines sustained oral fiber supplementation for patients undergoing treatment for hematological malignancies. Patients undergoing cancer treatment, including donor stem cell transplantation often develop oral and gastrointestinal damage from chemotherapy, radiotherapy, or graft-versus-host disease. Oral fiber nutrition support may improve overall nutrition, support a normal gut microbiome (bacteria that live in the gut) and/or improve gut function in patients undergoing treatment for hematological malignancies.

What is being tested

• Kate Farms 1.0 (dietary supplement)
• Standard of Care Nutritional Support (dietary supplement)
• Survey Administration (other)
• Dietary Supplement (dietary supplement)
• Biospecimen Collection (procedure)
• Electronic Health Record Review (other)

Sponsor: Fred Hutchinson Cancer Center · Participants: 100 · Started: Jun 22, 2022

Contact the study team

• David Fredricks · Phone: 206-667-1935

Official record on ClinicalTrials.gov — NCT04829136

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.